RXi Pharmaceuticals to raise $8.35 million through private placement
RXi Pharmaceuticals Corporation, a US-based biopharmaceutical company, has entered into an agreement to raise $8.35 million through a private placement of its common stock at a price of $3.5 per share. The company also issues warrants to purchase up to 954,286 shares of common stock at an exercise price of $4.5 per share.
RXi Pharmaceuticals would use the proceeds from the placement to meet working capital needs and for general corporate purposes.
PPM is the leading U.S. entrepreneurial firm that specializes in writing private placement memorandums (PPM) and linking investors with entrepreneurs.
Since 1999, the founders of PPM have provided professional business writing services, such as a PPM or business plan, to more than 2,000 businesses worldwide. Our company is considered to be the most cost effective, efficient consultants for private placement memorandum development in the United States. We are Wall Street’s, and by extension, the New York private placement (PPM) leaders.
PPM.co’s main service is the creation of private placement memorandum regulation d (Reg. d) documents. However, we offer much more. In case the entrepreneur needs additional services, such as a business plan, website, or additional legal work, PPM can create one pricing package for all required documentation or service. Because we simultaneously work with many companies both in and out of the U.S., the ability to adapt to the individual needs – as well as to regional and global demands – helps our clients save needed capital and time.
We are leaders in:
• New York Private Placement
• Pharmaceuticals Private Placement
• Technology Private Placement
• Debt Private Placement
• Equity Private Placement
• Technology Private Placement Memorandum Writing
• New York Private Placement Memorandum Writing
• Pharmaceutical Private Placement Memorandum Writing
• Debt Private Placement Memorandum Writing
• Equity Private Placement Memorandum Writing